TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10325270

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 794
Study: 1972487

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (75 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 464807

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate 100 mg twice daily on postoperative days 5 through 10 and then 100 mg daily for six weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 45
Study: 30876445

Group type: EXPERIMENTAL
Intervention: Pelvic Support (PS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Pelvic Constraint (PC)
Number of subjects: 13
Study: 27914210

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) using egg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Egg elimination (EE) group
Number of subjects: 30
Study: 26002927

Group type: EXPERIMENTAL
Intervention: High coffee intake
Number of subjects: 93179

Group type: EXPERIMENTAL
Intervention: Genetically derived high coffee intake
Number of subjects: 93179

Group type: EXPERIMENTAL
Intervention: Per-allele meta-analysed odds ratios for type 2 diabetes
Number of subjects: 93179
Study: 23899532

Group type: EXPERIMENTAL
Intervention: S-1/cisplatin (CS)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: infusional 5-FU/cisplatin (CF)
Number of subjects: 1053
Study: 22201659

Group type: EXPERIMENTAL
Intervention: Exercise intervention started at the beginning of chemotherapy (EE)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Exercise intervention started at the completion of chemotherapy (CE)
Number of subjects: 66
Study: 19502623

Group type: EXPERIMENTAL
Intervention: New onset atrial fibrillation (AF)
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Warfarin use in patients with AF at discharge
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation therapy at discharge
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Triple therapy among patients with coronary stents
Number of subjects: 5745

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation in patients at highest risk of stroke (CHADS(2) score >=2)
Number of subjects: 5745
Study: 17313533

Group type: EXPERIMENTAL
Intervention: Electrogram (EGM) method for AVD programming
Number of subjects: 28

Group type: COMPARATOR
Intervention: Noninvasive methods for AVD programming
Number of subjects: 28
Study: 15251160

Group type: EXPERIMENTAL
Intervention: 2 mg ibandronate
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: 6 mg ibandronate
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 11334201

Group type: EXPERIMENTAL
Intervention: Maxima PRF Plus
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quantum
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Affinity NT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quadrox
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Affinity
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Capiox
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Optima
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hilite
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All oxygenators
Number of subjects: 90
Study: 9673431

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 or 5 mg once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine retard (10 or 20 mg twice daily)
Number of subjects: 20
Study: 7517477

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Combined index of pain-free walking distance, maximum walking distance, and pressure indices
Number of subjects: 188
Study: 3293372

Group type: EXPERIMENTAL
Intervention: Single bolus (150 ml or 175 ml depending on weight)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Split bolus (first bolus 100 or 125 ml, second bolus 50 ml)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bolus-drip (initial bolus 100 or 125 ml followed by rapid IV drip infusion of 50 ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bolus-drip method
Number of subjects: 90
Study: 30260268

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sleep hygiene counseling
Number of subjects: 0
Study: 28292334

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide Cement (CH)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Resin-modified Glass Ionomer Cement (RMGIC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Gutta Percha (Control)
Number of subjects: 27
Study: 26289557

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (conventional anti-HF therapies)
Number of subjects: 42
Study: 23282113

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 336
Study: 21843876

Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty (ALT) after topical betaxolol hydrochloride treatment
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IOP before ALT
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: treating surgeon
Number of subjects: 127
Study: 19515732

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet with close supervision by a dietitian and provision of basic foods
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mediterranean-style diet (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet with close supervision
Number of subjects: 90
Study: 16377363

Group type: EXPERIMENTAL
Intervention: PTSD
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Panic disorder
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Typical heavy drinking
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Frequent drinking
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Co-occurrence of two or more anxiety and/or mood disorders
Number of subjects: 614
Study: 14763921

Group type: EXPERIMENTAL
Intervention: Graves' disease (GD) patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Hashimoto's thyroiditis (HT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Graves' disease (GD)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Thyroid autonomy (TA)
Number of subjects: 43
Study: 11182175

Group type: EXPERIMENTAL
Intervention: Telmisartan 10 mg once daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Telmisartan 20 mg once daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg once daily
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg once daily
Number of subjects: 378

Group type: COMPARATOR
Intervention: Enalapril 10 mg twice daily
Number of subjects: 378
Study: 9156375

Group type: EXPERIMENTAL
Intervention: Hydrophilic acidic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrophilic basic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrophobic acidic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrophobic basic liquid enema (45 micrograms nicotine base/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral solution (45 micrograms nicotine base/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous nicotine (15 micrograms nicotine base/kg)
Number of subjects: 30
Study: 8097304

Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (100-150 micrograms/kg)
Number of subjects: 30
Study: 2877702

Group type: EXPERIMENTAL
Intervention: d-propranolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31568099

Group type: EXPERIMENTAL
Intervention: Virtual perspective-taking intervention
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 436
Study: 29710760

Group type: EXPERIMENTAL
Intervention: Live action observation training (AOT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Video action observation training (AOT)
Number of subjects: 12
Study: 26374171

Group type: EXPERIMENTAL
Intervention: Collagen-stabilized anorganic bovine bone (ABBM-C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anorganic bovine bone + autogenous bone (ABBM + AB)
Number of subjects: 40
Study: 25145781

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Wuzhi capsules (WZC) + corticosteroids
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus + corticosteroids
Number of subjects: 60
Study: 22205241

Group type: EXPERIMENTAL
Intervention: 800 MBq I‐131 (low dose)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 3700 MBq I‐131 (high dose)
Number of subjects: 108
Study: 21147441

Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg) infused at 1 mg/sec
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ajmaline (1 mg/kg) infused over 10 minutes
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rapid infusion rate (assessed retrospectively during 386 challenges)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Slow infusion rate (assessed during the study)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rapid infusion rate (assessed during the study)
Number of subjects: 32
Study: 18056188

Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoid therapy
Number of subjects: 74
Study: 16265847

Group type: EXPERIMENTAL
Intervention: Continuous axillary brachial plexus block with 10 ml 0.75% ropivacaine loading dose followed by 4-5 ml per hour infusion for up to three days (Group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No continuous analgesia postoperatively (Group B)
Number of subjects: 18
Study: 12410195

Group type: EXPERIMENTAL
Intervention: 1% Permethrin Creme Rinse (1% PLT) without combing
Number of subjects: 95

Group type: COMPARATOR
Intervention: 1% Permethrin Creme Rinse (1% PLT) with adjunctive combing
Number of subjects: 95
Study: 9857653

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) mast cell analysis using Carnoy's solution as a fixative and 0.5% solution of Toluidine blue for staining.
Number of subjects: 38
Study: 7837931

Group type: EXPERIMENTAL
Intervention: eptastigmine 12mg tid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: eptastigmine 20mg tid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: eptastigmine 28mg tid
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: eptastigmine 48mg tid
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 2231482

Group type: COMPARATOR
Intervention: Normal running (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Withdrawal from running (experimental group)
Number of subjects: 40
Study: 27539

Group type: EXPERIMENTAL
Intervention: Clobazam (30 to 40 mg/day in three divided doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Diazepam (15 to 20 mg/day in three divided doses)
Number of subjects: 40
Study: 31883327

Group type: EXPERIMENTAL
Intervention: Fosfomycin (4 g dose intravenously 3 hours before catheter placement and removal)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 30728754

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Location of hormone replacement therapy
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Information received about HRT
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Physicians' counselling and involvement
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Knowledge of complications associated with HRT
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Employment status
Number of subjects: 1052
Study: 28887069

Group type: EXPERIMENTAL
Intervention: BREATHE transitional care program
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 26255088

Group type: EXPERIMENTAL
Intervention: 2PN Cryo group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Blast Cryo group
Number of subjects: 140
Study: 23337838

Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119
Study: 21088920

Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 2155

Group type: COMPARATOR
Intervention: White patients
Number of subjects: 2155
Study: 19051273

Group type: EXPERIMENTAL
Intervention: Clinically significant (CS) change in symptoms of ADHD and ODD
Number of subjects: 0

Group type: COMPARATOR
Intervention: No clinically significant (CS) change in symptoms of ADHD and ODD
Number of subjects: 0
Study: 16678550

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg for 2 days, then two 50 mg doses 12 hours apart for 5 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15361807

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Divalproex and Carbamazepine
Number of subjects: 0
Study: 11786648

Group type: EXPERIMENTAL
Intervention: DAG (20 g daily for 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: TAG (20 g daily for 12 weeks)
Number of subjects: 27
Study: 9403748

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (28 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mild hypothermia (34 degrees C)
Number of subjects: 0
Study: 8133022

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine taken in the morning
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine taken in the evening
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medication-Event-Monitoring System (MEMS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Days with missed medication removed from analysis
Number of subjects: 20
Study: 3499896

Group type: EXPERIMENTAL
Intervention: Antimotion sickness medications scopolamine:d‐amphetamine (0.4:5.0 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Promethazine:ephedrine (25:60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naproxyn (275 or 550 mg)
Number of subjects: 0
Study: 30950739

Group type: EXPERIMENTAL
Intervention: Short-term intensive voice therapy (IVT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Individual IVT (IVT-I)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group IVT (IVT-G)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Long-term traditional voice therapy (TVT)
Number of subjects: 46
Study: 29395938

Group type: EXPERIMENTAL
Intervention: Geriatrician-performed comprehensive geriatric care (CGC)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 368
Study: 26672793

Group type: EXPERIMENTAL
Intervention: Integrated intervention (cognitive behavioural therapy)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual counselling care
Number of subjects: 37
Study: 24508419

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) at a fixed dose level of 0.6 U/kg for 6 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Insulin detemir at a fixed dose level of 0.6 U/kg for 6 days
Number of subjects: 59
Study: 22171564

Group type: EXPERIMENTAL
Intervention: 50 U/kg rhC1INH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 U/kg rhC1INH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 20435375

Group type: EXPERIMENTAL
Intervention: Post-discharge surgical site infections (SSIs)
Number of subjects: 622683

Group type: COMPARATOR
Intervention: Common risk indices
Number of subjects: 622683
Study: 18566798

Group type: EXPERIMENTAL
Intervention: Watching live arthroscopic views (group W)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 63
Study: 14759562

Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin (AM) concentration in patients with PAOD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Plasma adrenomedullin (AM) concentration in patients without PAOD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Correlation of plasma AM concentration with inflammatory parameters
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Plasma levels of mature and intermediate forms of AM
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Step-up of mature form of AM from femoral artery to saphenous vein
Number of subjects: 72
Study: 11545752

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study: 14655848

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy (CBT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined Group Psychoeducation and Fluoxetine (GPF)
Number of subjects: 51
Study: 7951808

Group type: EXPERIMENTAL
Intervention: Homemade cereal‐based oral rehydration therapy (HC‐ORT, n = 103)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Glucose‐based oral rehydration solution (G‐ORS, n = 98)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Cereal‐based oral rehydration solution (C‐ORS, n = 90)
Number of subjects: 291
Study: 3311117

Group type: EXPERIMENTAL
Intervention: 400 micrograms salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.6 mg salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29773484

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 8 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 26525425

Group type: COMPARATOR
Intervention: Control
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Stunted
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Recovered
Number of subjects: 130
Study: 23382092

Group type: EXPERIMENTAL
Intervention: Lifestyle management and sibutramine
Number of subjects: 61
Study: 21682757

Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant growth hormone) for 12 months
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 6 months followed by LB03002 for 6 months
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: LB03002 (sustained-release recombinant growth hormone)
Number of subjects: 11
Study: 20172051

Group type: EXPERIMENTAL
Intervention: CeO(2) nanoparticles; pretreatment with varying concentrations 24 hours before radiation exposure.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CeO(2) nanoparticles; intraperitoneal injections before radiation exposure.
Number of subjects: 0
Study: 18343738

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy combined with probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative therapeutic options (immunotherapy, ion-exchange resins, new drugs)
Number of subjects: 0
Study: 16319952

Group type: EXPERIMENTAL
Intervention: Carmustine (300 mg/m2) + Melphalan (200 mg/m2)
Number of subjects: 49
Study: 13678769

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 3204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3204
Study: 11052393

Group type: EXPERIMENTAL
Intervention: Individually tailored sensory and coping information about analgesic side effects
Number of subjects: 43

Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 43
Study: 8686822

Group type: EXPERIMENTAL
Intervention: Group 1 (first on the operating list)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group 2 (4-5 hours later on the operating list)
Number of subjects: 60
Study: 1425158

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 20
Study: 2857213

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630
Study: 31468171

Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21
Study: 29641245

Group type: EXPERIMENTAL
Intervention: Energy Resonance by Cutaneous Stimulation (ERCS)
Number of subjects: 318

Group type: COMPARATOR
Intervention: No ERCS (control group)
Number of subjects: 318
Study: 27986129

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning prior to PCI
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (only PCI)
Number of subjects: 251
Study: 24942592

Group type: EXPERIMENTAL
Intervention: ABMSCs transplantation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Entecavir treatment
Number of subjects: 56
Study: 22237722

Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (SES) applied with different electrode positions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control subjects (age- and gender-matched)
Number of subjects: 10
Study: 20357150

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 63
Study: 17373176

Group type: EXPERIMENTAL
Intervention: Desonide hydrogel 0.05%
Number of subjects: 425

Group type: COMPARATOR
Intervention: Hydrogel vehicle
Number of subjects: 425
Study: 14510994

Group type: EXPERIMENTAL
Intervention: N-chlorotaurine (NCT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloramine T (CAT)
Number of subjects: 40
Study: 11127439

Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment started 3.2 ± 1.7 hours after MI
Number of subjects: 845

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 845
Study: 8747506

Group type: EXPERIMENTAL
Intervention: Blood ethanol concentrations (0.00%, 0.01‐0.049%, 0.050‐0.099%, 0.10‐0.15%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increased punishment certainty or severity
Number of subjects: 10
Study: 1575341

Group type: EXPERIMENTAL
Intervention: 26-G needle
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: 27-G needle
Number of subjects: 730